Иммунохимия и иммунопатология

Utilizing Major Allergens in Prophylactic Cell Therapy: A Novel Approach to Preventing IgE-mediated Allergies

Abstract

Narluia Eaga*

Furthermore, translating preclinical findings into clinical applications poses logistical and regulatory challenges. Clinical trials evaluating prophylactic cell therapy in human subjects must adhere to strict regulatory guidelines and standards for safety, efficacy and ethical conduct. Long-term follow-up and monitoring are also necessary to assess the durability and effectiveness of allergy prevention strategies. Despite these challenges, the concept of harnessing major allergens for prophylactic cell therapy represents a promising paradigm shift in allergy prevention. By utilizing specialized cell subsets, such as regulatory T cells or tolerogenic dendritic cells, engineered to target major allergens, it is possible to orchestrate antigen-specific immune responses that mitigate allergic sensitization and promote immune tolerance.